Pharmaceutical Supplier Secure SEK 3.19B Anesthesia & Plasma Framework

Standfirst

A group of nineteen pharmaceutical suppliers has been appointed to a major framework agreement for the supply of anesthesia and plasma medicines to Region Blekinge in Sweden. The contract carries a re estimated framework value of 3.19 billion SEK and operates without the reopening of competition for individual call offs. This procurement highlights the Swedish public sector strategy to ensure a resilient and diversified supply chain for critical hospital medications.

Introduction

The secure and uninterrupted supply of critical pharmaceuticals is a foundational pillar of modern public healthcare systems. In Sweden, regional health authorities are increasingly utilizing centralized framework agreements to manage the procurement of essential medicines, ensuring both clinical availability and fiscal responsibility. The recent award for anesthesia and plasma medicines by Region Blekinge exemplifies this strategic approach to public procurement.

By establishing a multi supplier framework, the contracting authority mitigates the risk of stockouts and supply chain disruptions that can directly impact patient care. The agreement allows the region to draw upon a broad portfolio of approved products from nineteen distinct large economic operators. This structure provides healthcare professionals with the necessary clinical flexibility while maintaining strict control over public expenditure.

Why This Contract Matters

This framework agreement is vital for maintaining the operational integrity of surgical and critical care units within the region. Anesthesia and plasma medicines are essential for life saving procedures, making their reliable availability a non negotiable requirement for public health services. For the pharmaceutical industry, securing a position on this list guarantees access to a stable and predictable revenue stream within the Swedish public sector. The procurement also demonstrates how public buyers can leverage collective demand to secure favorable terms without compromising on clinical quality or safety standards.

Contract Timeline

The procurement process culminated in the formal selection of the winning suppliers on May 27, 2026. Following the mandatory administrative and standstill periods, the framework contracts were officially concluded on June 2, 2026. The contract awards notice was subsequently published in the Official Journal of the European Union on September 7, 2026. This timeline reflects a standard and transparent execution of public procurement regulations in Sweden.

Contract Overview

The procurement is structured as a framework agreement without the reopening of competition. This means that the terms, including pricing, were fixed during the initial tender evaluation, and individual purchase orders will be issued directly based on these pre agreed conditions. The re estimated value of the framework agreement is set at 3,192,000,000.00 SEK. Nineteen distinct suppliers were selected for the single lot, ensuring a wide array of product options for the healthcare providers.

Key Contract Details

Project Scope

The scope of this contract covers the supply of a wide range of anesthesia and plasma derived medicinal products. These products are classified under the primary CPV code for pharmaceutical products. The suppliers are responsible for ensuring the timely delivery of these critical items to regional healthcare facilities in accordance with strict pharmaceutical storage and handling regulations. The agreement does not include strategic procurement aims beyond the standard requirement for reliable supply.

About the Contracting Authority

Region Blekinge is the primary contracting authority for this procurement. It is a regional public authority responsible for providing healthcare services and managing public health infrastructure within Blekinge County, Sweden.

About the Organisations Involved

Region Blekinge is the primary contracting authority and buyer. It manages regional healthcare services and drives the procurement of essential medical supplies for its hospitals and clinics.

CSL Behring Aktiebolag is a successful bidder and a large economic operator. The company specializes in plasma derived therapies and vaccines, bringing significant expertise to the anesthesia and plasma medicine supply chain.

Accord Healthcare AB is a successful bidder and a large economic operator. It is a major player in the generic pharmaceutical market, offering cost effective alternatives for hospital medications.

Takeda Pharma AB is a successful bidder and a large economic operator. The company provides a broad portfolio of specialized medicines, including critical care and plasma derived products.

hameln pharma AB is a successful bidder and a large economic operator. It focuses on injectable medicines and anesthesia products, ensuring reliable supply for surgical procedures.

Abcur AB is a successful bidder and a large economic operator. The company supplies a wide range of hospital pharmaceuticals and emergency medicines to the Swedish healthcare sector.

Baxter Medical Aktiebolag is a successful bidder and a large economic operator. It is a global leader in hospital products, including anesthesia and critical care solutions.

Fresenius Kabi AB is a successful bidder and a large economic operator. The company specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition.

Viatris AB is a successful bidder and a large economic operator. It provides a diverse portfolio of generic and branded pharmaceuticals to healthcare systems across Europe.

FrostPharma AB is a successful bidder and a large economic operator. The company is known for its reliable distribution of hospital pharmaceuticals and critical care products in the Nordic region.

B. Braun Medical Aktiebolag is a successful bidder and a large economic operator. It is a leading provider of healthcare and medical products, including anesthesia and pain management solutions.

Aguettant Nordic ApS is a successful bidder and a large economic operator. The company specializes in injectable medicines for anesthesia and intensive care.

Octapharma Nordic AB is a successful bidder and a large economic operator. It is a major supplier of human protein medicines, including plasma derived therapies.

Orifarm Generics AB is a successful bidder and a large economic operator. The company focuses on providing high quality generic medicines to the public healthcare sector.

Abboxia AB is a successful bidder and a large economic operator. It distributes a wide range of pharmaceutical products to hospitals and pharmacies across Sweden.

Unimedic Pharma AB is a successful bidder and a large economic operator. The company specializes in the distribution of specialized hospital medicines and medical devices.

Sandoz A/S is a successful bidder and a large economic operator. It is a global leader in generic and biosimilar medicines, ensuring broad access to essential treatments.

Aspen Pharma Ireland Limited is a successful bidder and a large economic operator. The company has a strong presence in the anesthesia and specialty care pharmaceutical markets.

Stragen Nordic A/S is a successful bidder and a large economic operator. It focuses on the development and distribution of innovative pharmaceutical products in the Nordic region.

Oresunda Pharma ApS is a successful bidder and a large economic operator. The company provides specialized pharmaceutical solutions and distribution services to healthcare providers.

Grifols Nordic AB was a non winning tenderer for this lot. It is a large economic operator specializing in plasma derived medicines, indicating strong competition in this specific therapeutic area.

Förvaltningsrätten i Växjö is the review organisation. This administrative court handles any legal appeals or disputes related to public procurement procedures in the region.

Procurement Analysis

The open procedure attracted a highly competitive response, with twenty bids received for the single lot. The award criteria were based entirely on price, carrying a weight of 100 percent. This binary evaluation method indicates that all submitted bids met the stringent technical and clinical minimum requirements outlined in the bidding documents. Consequently, the competition focused purely on financial efficiency, driving down costs for the public buyer while ensuring all baseline clinical standards were satisfied.

Additional Procurement Facts

The procurement is covered by the Government Procurement Agreement, which allows international suppliers to participate, although the successful bidders are primarily established within the European Economic Area. The project is not financed with European Union funds, relying instead on the regional healthcare budget. No dynamic purchasing system was utilized for this specific tender result.

Market & Industry Perspective

The Swedish public pharmaceutical market is characterized by a high degree of consolidation, with large economic operators dominating the supply of specialized hospital medicines. The presence of nineteen winners on a single framework indicates that the contracting authority values supplier diversity to mitigate the risk of supply chain disruptions. This approach ensures that if one manufacturer faces production delays, alternative approved products remain immediately available to healthcare providers. The absence of bids from micro, small or medium enterprises reflects the high regulatory and logistical barriers to entry in the hospital pharmaceutical sector.

Economic Significance

A re estimated framework value of 3.19 billion SEK represents a substantial allocation of public healthcare spending. This investment supports the domestic and regional distribution networks of major pharmaceutical companies, ensuring the continued availability of critical medical supplies. By securing these prices in advance, the region achieves significant budgetary predictability and protects against market volatility.

Future Procurement Opportunities

Suppliers who were not successful should monitor the official Tenders Portal for upcoming framework renewals or new lots covering different therapeutic areas. As technology and clinical guidelines evolve, public institutions will continuously generate new tenders opportunities for medication refreshes. Stakeholders should also track the Latest Active Tenders Procurement notices to anticipate upcoming infrastructure and supply projects in the broader Swedish healthcare sector. The dynamic nature of public procurement means that new Live Notices for Tenders will emerge as regional authorities update their clinical requirements.

Opportunities for Suppliers

While the primary framework positions have been awarded, specialized logistics providers and cold chain transport companies can find valuable subcontracting opportunities with the primary winners. Additionally, manufacturers of specific generic alternatives may explore partnerships with the appointed distributors to expand their market reach within the public sector.

What Businesses Should Watch

Industry observers should monitor the activation rate of this framework agreement to gauge actual public sector demand for these specific pharmaceutical products. The reliance on a price only evaluation model will be a key metric for future tender evaluations in similar therapeutic categories. Stakeholders should also review Live Notices for Tenders to anticipate upcoming infrastructure projects and supply chain modernizations in the region. Any shifts in clinical guidelines regarding anesthesia or plasma products will directly influence future RFPs and RFQs in this market.

SwedenTenders.com Procurement Intelligence

This contract represents a clear trend in European public procurement toward the use of multi supplier framework agreements to ensure supply chain resilience for critical medicines. By appointing nineteen different providers for a single therapeutic category, the Swedish regional authority mitigates the risk of stock shortages and manufacturer delays that have historically plagued public healthcare systems. This strategy prioritizes operational continuity and clinical flexibility over the traditional model of selecting a single exclusive supplier.

Strategically, this award is important because it demonstrates a shift toward binary quality evaluations in high value medical tenders. By assigning 100 percent weight to price, the buyer effectively pre qualified all compliant bidders based on their ability to meet stringent clinical and regulatory baselines. Suppliers can learn that meeting these technical minimums is now the primary hurdle, rather than competing solely on marginal quality differences during the initial framework establishment. To position themselves for future contracts, relevant suppliers must invest in supply chain transparency and ensure their product catalogs align with national clinical guidelines.

Future contracts in this market are likely to feature even stricter supply chain security mandates alongside price competition. Companies that proactively develop resilient distribution networks and can guarantee uninterrupted delivery will hold a distinct advantage when responding to future public procurement solicitations. The continued reliance on framework agreements without reopening of competition suggests that buyers value administrative efficiency and speed of ordering above all else in critical care scenarios.

Supplier Takeaways

• Multi supplier framework agreements are increasingly used to guarantee supply chain resilience in public healthcare procurement.
• Meeting strict clinical and regulatory minimums is a primary gateway for winning government pharmaceutical contracts.
• The real competition often shifts to the initial bid phase when frameworks are awarded without reopening of competition.
• Specialized logistics and cold chain providers can find valuable subcontracting opportunities with primary framework winners.

Key Takeaways

• Nineteen suppliers were awarded positions on a framework agreement for anesthesia and plasma medicines.
• The re estimated value of the framework agreement is 3.19 billion SEK.
• The award criteria was based 100 percent on price, reflecting a mature market for standardized hospital pharmaceuticals.
• Twenty bids were received, indicating strong competition among large economic operators.
• The framework operates without reopening of competition, ensuring rapid order fulfillment for critical care needs.

Conclusion

This framework agreement secures a reliable and diversified supply of critical anesthesia and plasma medicines for Region Blekinge. The multi supplier award structure ensures competitive tension and operational resilience for the duration of the contract. As the region continues to modernize its healthcare delivery, this procurement model will likely serve as a blueprint for future pharmaceutical acquisitions.

Source: Tenders Electronic Daily (TED), Contract Award Notice 612912-2026, Official Journal of the European Union, published on 07/09/2026.